COVID Vaccine

Instead of the JN.1, the U.S. health regulator asks the manufacturers to update the new shots to target the KP.2 variant

The company cited Gavi's failure to procure the 350 million doses it had agreed to buy in May last year for the COVAX facility

The drugmaker, which developed and sells the vaccine with Germany's BioNTech said last week that it is targetting a range of $110…

AstraZeneca's vaccine has struggled to compete globally with those from Pfizer Inc/BioNTech SE and Moderna Inc, whose shots use…

BBV154 is an intra-nasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine

President Joe Biden's administration expects to run out of federal funding for buying and distributing COVID-19 vaccines by…

As per a study, published in the journal 'EMBO Molecular Medicine,' the vaccine showed promising results in mice, and the…

The UK medicines regulator (MHRA) approved the so-called bivalent vaccine made by Moderna as a booster for adults

Moderna said its decision to develop the bivalent vaccines was based on different market preferences for shots against the…

The company's vaccine, based on an earlier strain of the virus, has not yet been authorised in the US, and is currently under FDA…